

## NEWSLETTER

*Dear Participants of the COST Action NOAR, since the very first newsletter in February a lot has happened, both within our Action as well as in the global community of Targeted Alpha Therapy with Astatine-211. Some of these news and events you will find shortly described herein.*

*/Emma Aneheim -Vice Chair*

### Global NOAR meeting in Coimbra

The Global NOAR meeting in Coimbra, Portugal that took place May 9-11<sup>th</sup> was a great success with > 100 participants, not only from Europe but also from USA, Japan, China and South Africa. Twelve companies were represented through an industrial exhibition, round table discussion and presentations. Other presentations and discussions included e.g. a status update from FZ Jülich regarding the Cyclone XP30 installation for astatine production, regulatory issues around the use of astatine with input from NMEu and STSM presentations from two young researchers. For more info visit the Action webpage and LinkedIn.



### Future Linac production of Astatine

In an online WG1 meeting in May, Nusano Inc. based in Utah, USA, presented a compelling plan to produce extensive amounts of astatine using novel linear accelerator technology; [Nusano to Present Production Capabilities to European Radiopharmaceuticals Working Group - Nusano](#)

### NOAR conference dissemination



Our Action was presented both with poster and presentation at the IAEA symposium ISTR, in Vienna, Austria in April. In addition, both astatine and our Action was very well represented at the 12th Targeted Alpha Therapy summit in Cape Town, South Africa, in February/March.

### the World Astatine Community - WAC

At TAT 12 in Cape Town, South Africa, our Action Chair, Jean-Francois Gestin together with Ethan Balkin, USA, and Takashi Nakano, Japan, launched the creation of the World Astatine Community, WAC. After the completion of NOAR, WAC will continue the important work that we have started but on a global scale. Work will continue to set the frames and decide on the format of WAC. For any questions around this, contact J-F Gestin; [jean-francois.gestin@univ-nantes.fr](mailto:jean-francois.gestin@univ-nantes.fr)

### Change in WG4 leadership

Working group 4, Clinical Applications in Nuclear Medicine, has been re-structured where Alexandre Lugat, Nantes, France, is stepping in for the leadership. If you want to take active part in this WG do not hesitate to contact Alexandre, and especially encourage your relevant clinical colleagues to do so, as more input from this part of the community is needed; [alexandre.lugat@chu-nantes.fr](mailto:alexandre.lugat@chu-nantes.fr)

Don't miss out on applying for Short Term Scientific Missions and ITC Conference grants! Check out the webpage for more info.